Published in PLoS One on December 06, 2011
Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med (2014) 6.95
Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin Cancer Res (2012) 2.66
Novel targets in non-small cell lung cancer: ROS1 and RET fusions. Oncologist (2013) 2.04
Molecular pathways: ROS1 fusion proteins in cancer. Clin Cancer Res (2013) 1.94
Tyrosine kinase gene rearrangements in epithelial malignancies. Nat Rev Cancer (2013) 1.80
Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS. Front Oncol (2014) 1.20
Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins. Proc Natl Acad Sci U S A (2013) 1.19
PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations. Proc Natl Acad Sci U S A (2015) 0.97
Small cell ovarian carcinoma: genomic stability and responsiveness to therapeutics. Orphanet J Rare Dis (2013) 0.93
The genomic landscape of TP53 and p53 annotated high grade ovarian serous carcinomas from a defined founder population associated with patient outcome. PLoS One (2012) 0.89
Mouse model for ROS1-rearranged lung cancer. PLoS One (2013) 0.88
A new spontaneously transformed syngeneic model of high-grade serous ovarian cancer with a tumor-initiating cell population. Front Oncol (2014) 0.86
Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes. Oncotarget (2015) 0.86
Contribution of the PALB2 c.2323C>T [p.Q775X] founder mutation in well-defined breast and/or ovarian cancer families and unselected ovarian cancer cases of French Canadian descent. BMC Med Genet (2013) 0.84
High levels of genomic aberrations in serous ovarian cancers are associated with better survival. PLoS One (2013) 0.82
PIST (GOPC) modulates the oncogenic voltage-gated potassium channel KV10.1. Front Physiol (2013) 0.81
The democratization of the oncogene. Cancer Discov (2014) 0.81
ROS1 immunohistochemistry among major genotypes of non-small-cell lung cancer. Clin Lung Cancer (2014) 0.80
Detection of lung adenocarcinoma with ROS1 rearrangement by IHC, FISH, and RT-PCR and analysis of its clinicopathologic features. Onco Targets Ther (2015) 0.77
ROS1 rearrangement and response to crizotinib in Stage IV non-small cell lung cancer. Lung India (2017) 0.77
Novel high-grade serous epithelial ovarian cancer cell lines that reflect the molecular diversity of both the sporadic and hereditary disease. Genes Cancer (2015) 0.76
Crystallization and preliminary X-ray crystallographic studies of the coiled-coil domain of PIST. Acta Crystallogr Sect F Struct Biol Cryst Commun (2013) 0.76
Long time response with chemotherapy in ROS1 NSCLC patient with unusual metastatic site. Cancer Biol Ther (2016) 0.76
Novel roles for LIX1L in promoting cancer cell proliferation through ROS1-mediated LIX1L phosphorylation. Sci Rep (2015) 0.76
Low levels of IGFBP7 expression in high-grade serous ovarian carcinoma is associated with patient outcome. BMC Cancer (2015) 0.76
Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target. Histopathology (2016) 0.75
Proximal and distal regulation of the HYAL1 gene cluster by the estrogen receptor α in breast cancer cells. Oncotarget (2016) 0.75
LncRNAs expression profiling in normal ovary, benign ovarian cyst and malignant epithelial ovarian cancer. Sci Rep (2016) 0.75
Recent Advances in Targeting ROS1 in Lung Cancer. J Thorac Oncol (2017) 0.75
Integrated genomic analyses of ovarian carcinoma. Nature (2011) 47.72
Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A (1996) 29.54
High sensitivity mapping of methylated cytosines. Nucleic Acids Res (1994) 16.62
The UCSC Genome Browser database: update 2010. Nucleic Acids Res (2009) 16.58
Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell (1988) 10.29
Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A (1998) 9.66
Genomic instability--an evolving hallmark of cancer. Nat Rev Mol Cell Biol (2010) 7.11
Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst (2003) 5.64
Genome-wide SNP assay reveals structural genomic variation, extended homozygosity and cell-line induced alterations in normal individuals. Hum Mol Genet (2006) 5.50
Runs of homozygosity in European populations. Am J Hum Genet (2008) 5.34
Extended tracts of homozygosity in outbred human populations. Hum Mol Genet (2006) 4.53
Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst (2001) 4.14
Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol (2008) 3.68
Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma. PLoS One (2011) 3.10
Integrated study of copy number states and genotype calls using high-density SNP arrays. Nucleic Acids Res (2009) 3.09
Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol (2009) 2.94
Data mining using the Catalogue of Somatic Mutations in Cancer BioMart. Database (Oxford) (2011) 2.84
Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol (2005) 2.83
Runs of homozygosity reveal highly penetrant recessive loci in schizophrenia. Proc Natl Acad Sci U S A (2007) 2.81
Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21). Genes Chromosomes Cancer (2003) 2.67
Copy number variants, diseases and gene expression. Hum Mol Genet (2009) 2.66
Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res (2005) 2.48
Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas. Cancer Res (2009) 2.25
Chromosomal imbalance maps of malignant solid tumors: a cytogenetic survey of 3185 neoplasms. Cancer Res (1997) 2.14
SNP arrays in heterogeneous tissue: highly accurate collection of both germline and somatic genetic information from unpaired single tumor samples. Am J Hum Genet (2008) 2.00
Characterization of four novel epithelial ovarian cancer cell lines. In Vitro Cell Dev Biol Anim (2000) 1.91
Genetic analysis of benign, low-grade, and high-grade ovarian tumors. Cancer Res (1995) 1.91
Pathology and classification of ovarian tumors. Cancer (2003) 1.90
High-resolution single nucleotide polymorphism array analysis of epithelial ovarian cancer reveals numerous microdeletions and amplifications. Clin Cancer Res (2007) 1.81
ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice. Cancer Res (2006) 1.80
Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol (2007) 1.69
Oncogenic targeting of an activated tyrosine kinase to the Golgi apparatus in a glioblastoma. Proc Natl Acad Sci U S A (2003) 1.33
Regions of homozygosity and their impact on complex diseases and traits. Hum Genet (2010) 1.30
DNA extraction from formalin-fixed, paraffin-embedded tissue. Cold Spring Harb Protoc (2009) 1.28
Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential. Obstet Gynecol (2002) 1.24
Long-term survival and patterns of care in women with ovarian tumors of low malignant potential. Gynecol Oncol (2002) 1.23
Oncogenic activating mutations are associated with local copy gain. Mol Cancer Res (2009) 1.21
Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2. Cancer Res (1995) 1.18
Comparative genomic hybridization detects genetic imbalances in primary ovarian carcinomas as correlated with grade of differentiation. Cancer (2001) 1.14
Large-scale genomic analysis of ovarian carcinomas. Mol Oncol (2008) 1.12
Discrimination between serous low malignant potential and invasive epithelial ovarian tumors using molecular profiling. Oncogene (2005) 1.10
Frequency of mismatch repair deficiency in ovarian cancer: a systematic review This article is a US Government work and, as such, is in the public domain of the United States of America. Int J Cancer (2011) 1.09
Genetic factors in ovarian carcinoma. Curr Oncol Rep (2001) 1.09
Genome-wide autozygosity mapping in human populations. Genet Epidemiol (2009) 1.07
Loss of heterozygosity and transcriptome analyses of a 1.2 Mb candidate ovarian cancer tumor suppressor locus region at 17q25.1-q25.2. Mol Carcinog (2005) 1.07
Genetic alterations in epithelial ovarian tumors analyzed by comparative genomic hybridization. Hum Pathol (2002) 1.07
Micropapillary serous carcinoma of the ovary has distinct patterns of chromosomal imbalances by comparative genomic hybridization compared with atypical proliferative serous tumors and serous carcinomas. Hum Pathol (2002) 1.02
Evaluation of Kras gene mutation and copy number gain in non-small cell lung cancer. J Thorac Oncol (2011) 1.02
Detailed genetic and physical mapping of tumor suppressor loci on chromosome 3p in ovarian cancer. Cancer Res (1999) 1.02
Characterization of three new serous epithelial ovarian cancer cell lines. BMC Cancer (2008) 1.02
Methylation and expression analysis of 15 genes and three normally-methylated genes in 13 Ovarian cancer cell lines. Cancer Lett (2005) 1.01
Genomic and genealogical investigation of the French Canadian founder population structure. Hum Genet (2011) 1.00
Transfer of chromosome 3 fragments suppresses tumorigenicity of an ovarian cancer cell line monoallelic for chromosome 3p. Oncogene (2006) 0.99
Characterization of the 3p12.3-pcen region associated with tumor suppression in a novel ovarian cancer cell line model genetically modified by chromosome 3 fragment transfer. Mol Carcinog (2009) 0.96
Methylation of tumor suppressor gene p16 and prognosis of epithelial ovarian cancer. Gynecol Oncol (2004) 0.96
Primary cultures of normal and tumoral human ovarian epithelium: a powerful tool for basic molecular studies. Exp Cell Res (1994) 0.96
Trisomy 12 and K-ras-2 amplification in human ovarian tumors. Int J Cancer (1991) 0.94
Analysis of a new homozygous deletion in the tumor suppressor region at 3p12.3 reveals two novel intronic noncoding RNA genes. Genes Chromosomes Cancer (2006) 0.93
Mapping of chromosome 3p deletions in human epithelial ovarian tumors. Oncogene (1998) 0.92
Bilateral ovarian carcinoma: cytogenetic evidence of unicentric origin. Int J Cancer (1991) 0.92
Comparative genome hybridization reveals specific genomic imbalances during the genesis from benign through borderline to malignant ovarian tumors. Cancer Genet Cytogenet (2006) 0.91
Patterns of expression of chromosome 17 genes in primary cultures of normal ovarian surface epithelia and epithelial ovarian cancer cell lines. Oncogene (2003) 0.90
Analysis of ovarian borderline tumors using comparative genomic hybridization and fluorescence in situ hybridization. Genes Chromosomes Cancer (1999) 0.88
Transcriptome analysis of serous ovarian cancers identifies differentially expressed chromosome 3 genes. Mol Carcinog (2008) 0.87
Genetic alterations in ovarian borderline tumours and ovarian carcinomas. Eur J Obstet Gynecol Reprod Biol (1999) 0.86
Germline TP53 mutations in BRCA1 and BRCA2 mutation-negative French Canadian breast cancer families. Breast Cancer Res Treat (2007) 0.86
Aberrant hypermethylation of RASSF1A promoter in ovarian borderline tumors and carcinomas. Virchows Arch (2005) 0.85
Genetic alterations of serous borderline tumors of the ovary compared to stage I serous ovarian carcinomas. Cancer Genet Cytogenet (2006) 0.84
Comparative analysis of loss of heterozygosity of specific chromosome 3, 13, 17, and X loci and TP53 mutations in human epithelial ovarian cancer. Mol Carcinog (2002) 0.84
Molecular genetic analysis of a cell adhesion molecule with homology to L1CAM, contactin 6, and contactin 4 candidate chromosome 3p26pter tumor suppressor genes in ovarian cancer. Int J Gynecol Cancer (2009) 0.83
Differences in p16 gene methylation and expression in benign and malignant ovarian tumors. Gynecol Oncol (1999) 0.83
Serous borderline tumors of the ovary. A clinicopathologic, immunohistochemical, and quantitative study of 44 cases. Cancer (1992) 0.83
Loss of heterozygosity at chromosome 3p in epithelial ovarian cancer in China. Int J Gynecol Cancer (2002) 0.82
The use of cytogenetics in understanding ovarian cancer. Biomed Pharmacother (2004) 0.81
Genomic imbalances in ovarian borderline serous and mucinous tumors. Cancer Genet Cytogenet (2002) 0.80
Genetic analysis of benign ovarian tumors. Int J Cancer (2003) 0.78
Karyotypic characteristics of borderline malignant tumors of the ovary: trisomy 12, trisomy 7, and r(1) as nonrandom features. Cancer Genet Cytogenet (1996) 0.78
Frequent loss of heterozygosity on chromosomes 7 and 9 in benign epithelial ovarian tumours. Oncogene (1997) 0.76
ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med (2010) 13.07
Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med (2009) 5.63
Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst (2002) 3.25
Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas. J Pathol (2011) 2.64
Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol (2011) 2.50
Analysis of PALB2/FANCN-associated breast cancer families. Proc Natl Acad Sci U S A (2007) 2.41
Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma. J Pathol (2010) 2.04
Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a gynecologic oncology group study. J Clin Oncol (2011) 1.73
KIF1A, an axonal transporter of synaptic vesicles, is mutated in hereditary sensory and autonomic neuropathy type 2. Am J Hum Genet (2011) 1.66
Breast cancer, pregnancy, and breastfeeding. J Obstet Gynaecol Can (2002) 1.56
Molecular description of a 3D in vitro model for the study of epithelial ovarian cancer (EOC). Mol Carcinog (2007) 1.55
Impact of hemochromatosis gene (HFE) mutations on epithelial ovarian cancer risk and prognosis. Int J Cancer (2011) 1.52
Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. J Immunol Methods (2009) 1.48
Characterization of ovarian cancer ascites on cell invasion, proliferation, spheroid formation, and gene expression in an in vitro model of epithelial ovarian cancer. Neoplasia (2007) 1.45
A framework for biobank sustainability. Biopreserv Biobank (2014) 1.41
Expression and nuclear localization of ErbB3 in prostate cancer. Clin Cancer Res (2006) 1.36
Nuclear localization of nuclear factor-kappaB p65 in primary prostate tumors is highly predictive of pelvic lymph node metastases. Clin Cancer Res (2006) 1.30
Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer. Int J Cancer (2006) 1.27
Clinical trials in recurrent ovarian cancer. Int J Gynecol Cancer (2011) 1.27
Regulation of E2Fs and senescence by PML nuclear bodies. Genes Dev (2011) 1.25
A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity. Cancer Res (2012) 1.21
Tumor suppressor activity of the ERK/MAPK pathway by promoting selective protein degradation. Genes Dev (2013) 1.18
Expression of NF-kappaB in prostate cancer lymph node metastases. Prostate (2004) 1.18
Significant proportion of breast and/or ovarian cancer families of French Canadian descent harbor 1 of 5 BRCA1 and BRCA2 mutations. Int J Cancer (2004) 1.14
Global gene expression analysis of early response to chemotherapy treatment in ovarian cancer spheroids. BMC Genomics (2008) 1.13
Self-sampling is associated with increased detection of human papillomavirus DNA in the genital tract of HIV-seropositive women. Clin Infect Dis (2005) 1.13
H3K27 demethylation by JMJD3 at a poised enhancer of anti-apoptotic gene BCL2 determines ERα ligand dependency. EMBO J (2011) 1.12
BMP-2 signaling in ovarian cancer and its association with poor prognosis. J Ovarian Res (2009) 1.11
Discrimination between serous low malignant potential and invasive epithelial ovarian tumors using molecular profiling. Oncogene (2005) 1.10
PTP1B is an androgen receptor-regulated phosphatase that promotes the progression of prostate cancer. Cancer Res (2012) 1.10
The Meaning-Making intervention (MMi) appears to increase meaning in life in advanced ovarian cancer: a randomized controlled pilot study. Psychooncology (2010) 1.08
Comparative proteome analysis of human epithelial ovarian cancer. Proteome Sci (2007) 1.08
Loss of heterozygosity and transcriptome analyses of a 1.2 Mb candidate ovarian cancer tumor suppressor locus region at 17q25.1-q25.2. Mol Carcinog (2005) 1.07
Proteome profiling of human epithelial ovarian cancer cell line TOV-112D. Mol Cell Biochem (2005) 1.06
Human papillomavirus (HPV) DNA triage of women with atypical squamous cells of undetermined significance with cobas 4800 HPV and Hybrid Capture 2 tests for detection of high-grade lesions of the uterine cervix. J Clin Microbiol (2012) 1.05
Breast carcinoma-associated fibroblasts rarely contain p53 mutations or chromosomal aberrations. Cancer Res (2010) 1.04
Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148. J Clin Oncol (2008) 1.02
Characterization of three new serous epithelial ovarian cancer cell lines. BMC Cancer (2008) 1.02
SET complex in serous epithelial ovarian cancer. Int J Cancer (2006) 1.01
From gene profiling to diagnostic markers: IL-18 and FGF-2 complement CA125 as serum-based markers in epithelial ovarian cancer. Int J Cancer (2006) 1.01
Role of Pirh2 in mediating the regulation of p53 and c-Myc. PLoS Genet (2011) 0.99
Global analysis of chromosome X gene expression in primary cultures of normal ovarian surface epithelial cells and epithelial ovarian cancer cell lines. Int J Oncol (2007) 0.99
Independent role of phosphoinositol-3-kinase (PI3K) and casein kinase II (CK-2) in EGFR and Her-2-mediated constitutive NF-kappaB activation in prostate cancer cells. Prostate (2005) 0.99
Crk adaptor proteins act as key signaling integrators for breast tumorigenesis. Breast Cancer Res (2012) 0.98
EGFR and Her-2 regulate the constitutive activation of NF-kappaB in PC-3 prostate cancer cells. Prostate (2005) 0.98
Salvage treatment with high-dose-rate brachytherapy for isolated vaginal endometrial cancer recurrence. Gynecol Oncol (2005) 0.97
Characterization of the 3p12.3-pcen region associated with tumor suppression in a novel ovarian cancer cell line model genetically modified by chromosome 3 fragment transfer. Mol Carcinog (2009) 0.96
Specific variants in the MLH1 gene region may drive DNA methylation, loss of protein expression, and MSI-H colorectal cancer. PLoS One (2010) 0.95
Variation in rates of uptake of preventive options by Canadian women carrying the BRCA1 or BRCA2 genetic mutation. Open Med (2007) 0.95
Influence of monolayer, spheroid, and tumor growth conditions on chromosome 3 gene expression in tumorigenic epithelial ovarian cancer cell lines. BMC Med Genomics (2008) 0.94
An essential role for Ran GTPase in epithelial ovarian cancer cell survival. Mol Cancer (2010) 0.93
Protease inhibitor SERPINA1 expression in epithelial ovarian cancer. Clin Exp Metastasis (2010) 0.93
Small cell ovarian carcinoma: genomic stability and responsiveness to therapeutics. Orphanet J Rare Dis (2013) 0.93
BTN3A2 expression in epithelial ovarian cancer is associated with higher tumor infiltrating T cells and a better prognosis. PLoS One (2012) 0.93
NOXA and PUMA expression add to clinical markers in predicting biochemical recurrence of prostate cancer patients in a survival tree model. Clin Cancer Res (2007) 0.93
Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancer. BMC Cancer (2012) 0.92
Effect of ovarian cancer ascites on cell migration and gene expression in an epithelial ovarian cancer in vitro model. Transl Oncol (2010) 0.91
Chromosome 17q25 genes, RHBDF2 and CYGB, in ovarian cancer. Int J Oncol (2012) 0.91
Reprogramming of the transcriptome in a novel chromosome 3 transfer tumor suppressor ovarian cancer cell line model affected molecular networks that are characteristic of ovarian cancer. Mol Carcinog (2009) 0.90
Gata3 antagonizes cancer progression in Pten-deficient prostates. Hum Mol Genet (2013) 0.90
Low nuclear ErbB3 predicts biochemical recurrence in patients with prostate cancer. BJU Int (2007) 0.90
Large-scale independent validation of the nuclear factor-kappa B p65 prognostic biomarker in prostate cancer. Eur J Cancer (2013) 0.90
Patterns of expression of chromosome 17 genes in primary cultures of normal ovarian surface epithelia and epithelial ovarian cancer cell lines. Oncogene (2003) 0.90
Selected class I and class II HLA alleles and haplotypes and risk of high-grade cervical intraepithelial neoplasia. Int J Cancer (2008) 0.90
BTF4/BTNA3.2 and GCS as candidate mRNA prognostic markers in epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev (2008) 0.90